Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypertrophic Cardiomyopathy (HCM) clinical trials
2 of 3 indexed Hypertrophic Cardiomyopathy (HCM) trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Hypertrophic Cardiomyopathy (HCM): 3 US clinical trials tracked, 2 recruiting.
Hypertrophic Cardiomyopathy (HCM) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. The most active sponsor is Christopher Kramer, running 1 of these trials.
Enrollment posture brief
Registry condition hypertrophic-cardiomyopathy-hcm
OPEN 2 | RECR 67% | LATE 0 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Hypertrophic Cardiomyopathy (HCM) lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypertrophic Cardiomyopathy (HCM) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypertrophic Cardiomyopathy (HCM) is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
HCMR Re-Imaging Study
Christopher Kramer
NCT07054073
Large Language Models To Improve the Quality of Care of Cardiology Patients
Stanford University
NCT06935253
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb
NCT06372457
Phase Distribution
Phase data not available
Top Sponsors
Named interventions
Most-linked intervention names on Hypertrophic Cardiomyopathy (HCM) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypertrophic Cardiomyopathy (HCM) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypertrophic Cardiomyopathy (HCM) page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Hypertrophic Cardiomyopathy (HCM) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Christopher Kramer sponsors the most Hypertrophic Cardiomyopathy (HCM) trials on record, review their full trial history before evaluating a specific study. See Christopher Kramer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypertrophic Cardiomyopathy (HCM) condition card totals 3 registered trials; most-linked intervention Approved Hypertrophic Cardiomyopathy drug treatments; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.